On March 18, AMCP provided comments to the HHS Office of the National Coordinator for Health Information Technology regarding electronic prior authorization.
On March 9, AMCP joined 13 pharmacy organizations in urging President Biden to authorize pharmacists to order and administer oral antivirals to treat COVID-19 as part of the administration's Test to Treat policy.
AMCP provides feedback on CMS's proposal to redefine negotiated price as the lowest possible payment that a Part D plan will make to a pharmacy, inclusive of all price concessions.
On March 3, AMCP responded to a Request for Information from the Healthy Futures Subcommittee on Modernization, supporting legislative and regulatory solutions to remove barriers to coverage and payment for Digital Therapeutics in the Medicare program.
On Feb. 14, AMCP joined a pharmacy stakeholder letter supporting Dr. Robert Califf's nomination for FDA Commissioner, a post he previously held in 2016.
On Feb. 9, AMCP submitted comments to CMS supporting the agency's proposal to cover anti-amyloid monoclonal antibodies through the Coverage with Evidence Development pathway.
On Jan. 11, CMS released a proposed coverage decision that would cover the costs of monoclonal antibody treatments for Alzheimer's Disease patients only if they are enrolled in clinical trials.